|
2025
|
P/S
|
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic ... |
|
|
Invention
|
Crystalline forms of a magl inhibitor.
Described herein are crystalline forms of the MAGL inhibi... |
|
|
P/S
|
Sanitary preparations for medical purposes; dietetic preparations adapted for medical purposes; v... |
|
|
P/S
|
Sanitary preparations for medical purposes; dietetic preparations for medical use; vaccines; phar... |
|
|
Invention
|
Agent, uses and methods for treatment.
The present invention relates to monoclonal anti-Sortilin... |
|
|
Invention
|
Spiromacrocyclic orexin 2 receptor agonists.
The present invention relates to novel spiro-macroc... |
|
|
Invention
|
Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of... |
|
|
Invention
|
Compositions and methods for treating multiple system atrophy (msa).
The present invention relat... |
|
|
Invention
|
Compositions and methods for treating multiple system atrophy (msa). The present invention relate... |
|
2024
|
Invention
|
Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitros... |
|
|
Invention
|
Fusion proteins for use in treatment of thyroid eye disease. The present disclosure relates to me... |
|
|
Invention
|
Antibodies specific for hyperphosphorylated tau and methods of use thereof.
The present inventio... |
|
|
Invention
|
Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia.
The present invention r... |
|
|
Invention
|
Compositions and methods for treating synucleinopathies. The present invention relates to stable ... |
|
|
Invention
|
Combinational treatment. The present invention relates to a composition comprising Eptinezumab an... |
|
|
Invention
|
Spiromacrocyclic orexin 2 receptor agonists. The present invention relates to novel spiro-macrocy... |
|
|
Invention
|
Leucine-rich repeat kinase 2 (lrrk2) inhibitors. The present invention is directed to compounds o... |
|
|
Invention
|
Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibito... |
|
|
Invention
|
Acute treatment and rapid treatment of headache using anti-cgrp antibodies. Methods for rapid tre... |
|
|
Invention
|
Treatment of headache using anti-cgrp antibodies. Methods for immediate relief of migraine or hea... |
|
|
Invention
|
Leucine-rich repeat kinase 2 (lrrk2) inhibitors.
The present invention is directed to compounds ... |
|
|
Invention
|
Humanized anti-pacap antibodies and uses thereof.
The present invention is directed to antibodie... |
|
|
Invention
|
Treatment of opiod-induced pain. The present invention is directed to a method for treatment of p... |
|
2023
|
Invention
|
Arginine wash in protein purification.
The present invention relates to methods for isolating a ... |
|
|
Invention
|
Arginine wash in protein purification. The present invention relates to methods for isolating a p... |
|
|
Invention
|
Composition comprising zuclopenthixol. The present invention relates to a pharmaceutical composit... |
|
|
Invention
|
Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies.
Methods for ... |
|
|
Invention
|
Solid forms of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar, 10ar)-7-hydroxy-1-propyl-1,2,3,4,4a,5,... |
|
|
Invention
|
Process for the manufacture of (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-(((4ar,10ar)-7-hydroxy-1-propy... |
|
|
Invention
|
Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine.
The invention provides ... |
|
|
Invention
|
Macrocyclic leucine-rich repeat kinase 2 (lrrk2) inhibitors. The present invention is directed to... |
|
|
Invention
|
Process for the manufacturing of (6ar,10ar)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[... |
|
|
Invention
|
Lrrk2 inhibitors. The present invention is directed to compounds of formula I
The compounds ... |
|
|
Invention
|
Catecholamine prodrugs for use in the treatment of parkinson's disease. The present invention pro... |
|
|
Invention
|
Synthesis of a monoacylglycerol lipase inhibitor.
Described herein is the manufacture of MAGL in... |
|
|
Invention
|
Crystalline forms of a magl inhibitor. Described herein are crystalline forms of the MAGL inhibit... |
|
|
Invention
|
Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity.
New pharmaceutica... |
|
|
Invention
|
Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies. M... |
|
2022
|
Invention
|
Alcohol derivatives as kv7 potassium channel openers.
The present invention provides novel compo... |
|
|
Invention
|
Anti-cgrp antibody dosing and screening methods.
The present invention relates the use of monocl... |
|
|
Invention
|
Treatment of cluster headache using anti-cgrp antibodies.
Methods for treating cluster headache ... |
|
|
Invention
|
Method for determination of hyperphosphorylated tau in human cerebrospinal fluid by lc-ms.
The p... |
|
2021
|
Invention
|
New catecholamine prodrugs for use in the treatment of parkinson's disease.
The present inventio... |
|
|
Invention
|
Magl inhibitors.
Provided herein are substituted 1,1,1,3,3,3-hexafluoropropan-2-yl 6-azaspiro[2.... |
